title: [A Case of a Multidisciplinary Team Approach to Serious Hand-Foot Syndrome Induced by High-Dose Cytarabine Therapy].
abstract: A 40's year-old female patient with acute myeloblastic leukemia received high-dose cytarabine(HD-Ara-C)as her third induction therapy. Because the pharmacist in charge noticed on a prior interview that she had experienced a mild skin eruption similar to hand-foot syndrome(HFS)in the previous round oftherapy(idarubicin and cytarabine), heparinoid lotion and hypoallergenic soap were used to prevent HFS. However, HFS occurred on day 3, and further developed on day 6 to grade 3 with painful erythema, swelling, and paresthesia affecting the entire surface of both hands. We cared for her with moisturization, lifestyle guidance, rotation of steroid ointment, and occlusive dressing techniques according to a multidisciplinary team approach composed ofa hematologist, dermatologist, pharmacist, and nurse. Her symptoms resolved on day 40.
authors.affiliation: Dept. of Pharmacy, Ichinomiya Municipal Hospital.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Sakurada
authors.forename: Miki
authors.initials: M
authors.lastname: Aoi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Yuge
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Sugimura
authors.forename: Kunio
authors.initials: K
authors.lastname: Kitamura
authors.forename: Masumi
authors.initials: M
authors.lastname: Yamamura
authors.forename: Tomoya
authors.initials: T
authors.lastname: Tachi
authors.forename: Hitomi
authors.initials: H
authors.lastname: Teramachi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D004890:Erythema / Q000139:chemically induced / Q000628:therapy; D005260:Female; D060831:Hand-Foot Syndrome / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D010348:Patient Care Team; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D015255:Idarubicin